These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 1617509

  • 21. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W, Schmutzler H.
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
    Naylor CD, Armstrong PW.
    CMAJ; 1989 Jun 01; 140(11):1289-99. PubMed ID: 2497946
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA.
    N Engl J Med; 1995 Oct 12; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ.
    Ann Intern Med; 1994 May 15; 120(10):876-81; discussion 882-5. PubMed ID: 8154647
    [Abstract] [Full Text] [Related]

  • 29. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS, White HD.
    Pharmacoeconomics; 1993 Mar 15; 3(3):192-204. PubMed ID: 10172049
    [Abstract] [Full Text] [Related]

  • 30. Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
    Shammas NW, Zeitler R, Fitzpatrick P.
    Clin Cardiol; 1993 Apr 15; 16(4):283-92. PubMed ID: 8458108
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC.
    Internist (Berl); 1992 May 15; 33(5):364-5. PubMed ID: 1612871
    [No Abstract] [Full Text] [Related]

  • 33. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.
    Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, Simoons ML, Simes RJ, Lee KL, Topol EJ.
    Circulation; 1996 Sep 15; 94(6):1233-8. PubMed ID: 8822974
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
    Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB.
    Circulation; 1999 Jan 26; 99(3):370-6. PubMed ID: 9918523
    [Abstract] [Full Text] [Related]

  • 37. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy.
    Brody B, Wray N, Bame S, Ashton C, Petersen N, Harward M.
    Med Care; 1991 Sep 26; 29(9):899-910. PubMed ID: 1921539
    [Abstract] [Full Text] [Related]

  • 38. Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
    Kellett J, Clarke J.
    Med Decis Making; 1995 Sep 26; 15(4):297-310. PubMed ID: 8544674
    [Abstract] [Full Text] [Related]

  • 39. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Moen EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, Topol EJ.
    J Womens Health; 1997 Jun 26; 6(3):285-93. PubMed ID: 9201663
    [Abstract] [Full Text] [Related]

  • 40. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.
    Lancet; 1990 Jul 14; 336(8707):71-5. PubMed ID: 1975322
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.